efonidipine
Sign in to saveEfonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels. Drug Controller General of India (DCGI) has approved the use of efonidipine in India. It is launched under the brand name "Efnocar" (Zuventus Health care ltd, India).
Research
190 papers- Efonidipine-Induced Exanthematic Drug Eruption and Literature Review.Journal of cardiovascular pharmacology · 2019
- Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.Cardiovascular drug reviews · 2002
- Structural basis for efonidipine block of a voltage-gated Ca(2+) channel.Biochemical and biophysical research communications · 2019
- Efonidipine Inhibits JNK and NF-κB Pathway to Attenuate Inflammation and Cell Migration Induced by Lipopolysaccharide in Microglial Cells.Biomolecules & therapeutics · 2022
- Efonidipine Exerts Cerebroprotective Effect by Down-regulation of TGF-β/SMAD-2-Dependent Signaling Pathway in Diabetic Rats.Journal of molecular neuroscience : MN · 2021
via PubMed
Wikidata facts
- Mass
- 631.244737
Show 4 more facts
- chemical formula
- C₃₄H₃₈N₃O₇P
- canonical SMILES
- CC1=C(C(C(=C(N1)C)P2(=O)OCC(CO2)(C)C)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCN(CC4=CC=CC=C4)C5=CC=CC=C5
- subject has role
- diuretic
- Commons category
- Efonidipine
Sources (2)
via Wikidata · CC0
~8 min read
Encyclopedic overview
19 sectionsContents
- Structure Activity Relationship
- Mechanism of action
- Pharmacodynamics
- Pharmacokinetics
- Absorption
- Metabolism
- Elimination
- Indications
- Contraindications
- Precautions
- Drug Interactions
- Adverse Drug Reactions
- Lesser incidence of pedal edema (< 0.1%)
- Use in special population
- Administration to elderly
- Pregnancy and lactation
- Pediatric use
- References
- Further reading
Efonidipine (INN) is a dihydropyridine calcium channel blocker marketed by Shionogi & Co. of Japan. It was launched in 1995, under the brand name Landel (ランデル). The drug blocks both T-type and L-type calcium channels. Drug Controller General of India (DCGI) has approved the use of efonidipine in India. It is launched under the brand name "Efnocar" (Zuventus Health care ltd, India).
== Structure Activity Relationship == Efonidipine is a dual Calcium Channel Blocker (L & T-type). It has a unique chemical structure. The phosphonate moiety (Figure 1) at the C5 position of the dihydropyridine ring is considered to be important for the characteristic pharmacological profile of the drug. (figure-1) thumb|Figure-1:Efonidipine: Chemical Structure
Excerpted from Wikipedia’s “efonidipine” article, available under the CC BY-SA 4.0 licence.